Technology Networks
BASi Opens new Facility in Europe to Better Serve Pharmaceutical and Biotech Companies
The relocation to a new, upgraded facility with expanded laboratories provides clients with enhanced capabilities throughout Europe.
Thermo Fisher Scientific and NextGen Sciences Announce Collaboration
BRIMS Center will work with NextGen Sciences to develop and validate targeted SRM assays for peptides and proteins in biofluids and tissues.
Agilent Introduces Service to Help GC and LC Labs Demonstrate Test Quality and Calibration
Service leverages expertise in Pharma into chemical, food, flavors, forensics, other labs seeking ISO/IEC 17024-type certification.
VBI Researchers Develop new Method for Breast Cancer Biomarker Discovery
The method provides insight that how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs.
Force Spectroscopy of the Iron Atom in Heme Proteins
Northeastern University, Boston University, Argonne National Laboratory

Nuclear resonance vibrational spectroscopy (NRVS) selectively reveals the complete vibrational density of states (VDOS) of a Mössbauer probe nucleus within a protein. Frequency moments of the VDOS determine effective force constants for 57Fe at the active sites of cytochrome c (cyt c) and deoxymyoglobin (Mb).
No Impact of Dietary Iodine Restriction in Short Term Development of Hypothyroidism Following Fixed Dose Radioactive Iodine Therapy for Graves Disease
*Department of Endocrinology ,Nuclear Medicine and Clinical Biochemistry, Christian Medical College Vellore India 632004

To study the outcomes at 6 months after fixed dose 131I therapy for Graves’ disease (GD) with an iodine restricted diet.
Achieving Great Science : Bringing Together Physical Measurements and Chemical Analysis
ACD Labs

Many problems in analytical spectroscopy require insight from several different techniques to adequately resolve the problem. A common difficulty with using several techniques is often the ability to manage the various data types and making the data available for review, analysis and reporting.
Senior Director ADME
The RSA Group
Hatfield, Herts, UK
Mass Spectometry Scientist
Roswell Park Cancer Institute
Buffalo, NY, USA
Principal HTS Scientist
St. Jude Childrens Research Hospital
Memphis, TN, USA

Target Discovery World Congress, South San Francisco, CA, USA
04 August 2009 - 05 August 2009

Target Discovery World Congress will be a meeting focusing on the research looking to find new potential drugs for development. The topics will include presentations on the latest in screening platforms and new methods such as those in High Content and Label-Free Screening and will also focus on the work being done looking for new drug targets in some of the major protein families including Ion Channels, GPCRs, Protein Kinases, Nuclear Receptors and the Ubiquitin Pathway.
Molecular Diagnostics World Congress, South San Franscisco, CA, USA
06 August 2009 - 07 August 2009

Welcome to the 2nd Molecular Diagnostics World Congress, this year's event will take place at the South San Francisco Conference Center.
Advances in BioDetection Technologies, London England
09 October 2009 - 09 October 2009

Select Biosciences' 2nd Advances in BioDetection Technologies will offer attendees the opportunity to minimize time away from the office and travel costs whilst still providing an excellent overview of the sector and an opportunity to network with its key players.
Advances in Metabolic Profiling, Barcelona, Spain
05 November 2009 - 06 November 2009

Welcome to the 5th annual Advances in Metabolic Profiling conference and exhibition. This year's event will take place in Barcelona, the dynamic capital city of Catalonia.
  
Multiplexed Diagnostics 2009 Market Report
Published March 2009

Multiplexed diagnostics are the long-awaited ascendance of ’omics into healthcare. The promise of multiple measurements to characterize complexity is finally being realized.
Multiplexed Diagnostics 2008 Market Report
Published May 2008

Multiplexed diagnostics are the wild west of medicine. Technology is established, regulation is limited and the number of new biomarkers exploding. First-movers are grabbing biomarker territories, combining independent measurements for efficiency and mining molecules for multivariate panels. All the while demand is high for improving diagnoses and predicting responses to treatment. The challenges, however, are uncertain reimbursement, unclear business models and ever-intensifying competition. On
Novel ProteoPrep® 20 Immunoaffinity Depletion Resin for Human Plasma
Sigma Aldrich

Sigma’s ProteoPrep® 20 Plasma Immunodepletion Kit specifically removes 20 of the most abundant proteins from human plasma or serum in preparation for two-dimensional electrophoresis. The technology specifically removes twenty of the top high abundance proteins utilizing conventional antibodies coupled with small recombinant immunoaffinity ligands. The ProteoPrep 20 technology is advancing the frontier of biomarker discovery.